Compounded Tirzepatide Injectable

What Is Tirzepatide?

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that targets two hormonal pathways for weight loss. In the SURMOUNT clinical trials, it produced up to 22.5% body weight loss — making it the most effective weight loss medication ever studied. It works on both appetite and metabolism simultaneously.

How It Works

Unlike single-action GLP-1 drugs, tirzepatide activates both GIP and GLP-1 receptors. GIP (glucose-dependent insulinotropic polypeptide) enhances fat metabolism and improves insulin sensitivity, while GLP-1 reduces appetite and slows gastric emptying. This dual mechanism produces superior weight loss results compared to semaglutide alone.

What's Included

• Compounded tirzepatide vial (pharmacy-grade)
• Injection supplies (insulin syringes, alcohol swabs)
• Guided dose titration schedule
• Provider monitoring & check-ins
• Dietary and exercise guidance
• Monthly delivery to your door

Tirzepatide vs Semaglutide

• Weight loss: Tirzepatide ~22.5% vs semaglutide ~15% average body weight reduction
• Mechanism: Dual GIP/GLP-1 vs GLP-1 only
• Side effects: Similar GI side effects profile, but tirzepatide may have better tolerability for some
• Cost: Tirzepatide is typically more expensive due to newer formulation

Expected Results

• Weeks 1–4: Significant appetite reduction, early weight loss (4–6 lbs)
• Months 1–3: Accelerated weight loss of 2–3 lbs/week
• Months 3–6: Major body composition changes, improved metabolic health
• Month 6+: 15–22%+ body weight loss for most patients